Abstract:Tuberculosis (TB), caused by respiratory infection with Mycobacterium tuberculosis , remains a major global health threat. The only licensed TB vaccine, the one-hundred-year-old Bacille Calmette-Guérin has variable efficacy and often provides poor protection against adult pulmonary TB, the transmissible form of the disease. Thus, the lack of an optimal TB vaccine is one of the key barriers to TB control. Recently, the development of highly efficacious COVID-19 vaccines within one year accelerated the vaccine development process in human use, with the notable example of mRNA vaccines and adenovirus-vectored vaccines, and increased the public acceptance of the concept of the controlled human challenge model. In the TB vaccine field, recent progress also facilitated the deployment of an effective TB vaccine. In this review, we provide an update on the current virus-vectored TB vaccine pipeline and summarize the latest findings that might facilitate TB vaccine development. In detail, on the one hand, we provide a systematic literature review of the virus-vectored TB vaccines are in clinical trials, and other promising candidate vaccines at an earlier stage of development are being evaluated in preclinical animal models. These research sharply increase the likelihood of finding a more effective TB vaccine in the near future. On the other hand, we provide an update on the latest tools and concept that facilitating TB vaccine research development. We propose that a pre-requisite for successful development may be a better understanding of both the lung-resident memory T cell-mediated mucosal immunity and the trained immunity of phagocytic cells. Such knowledge could reveal novel targets and result in the innovative vaccine designs that may be needed for a quantum leap forward in vaccine efficacy. We also summarized the research on controlled human infection and ultra-low-dose aerosol infection murine models, which may provide more realistic assessments of vaccine utility at earlier stages. In addition, we believe that the success in the ongoing efforts to identify correlates of protection would be a game-changer for streamlining the triage of multiple next-generation TB vaccine candidates. Thus, with more advanced knowledge of TB vaccine research, we remain hopeful that a more effective TB vaccine will eventually be developed in the near future.

Progress on Mycobacterium tuberculosis vaccine development

Progress in immunology of tuberculosis and new vaccine development

Preclinical Progress of Subunit and Live Attenuated Mycobacterium tuberculosis Vaccines: A Review following the First in Human Efficacy Trial

Induction of an Immune-Protective T-Cell Repertoire with Diverse Genetic Coverage by a Novel Viral-Vectored Tuberculosis Vaccine in Humans

New Tuberculosis Vaccine Strategies: Taking Aim at Un-Natural Immunity

Tuberculosis vaccine development: from classic to clinical candidates

Tuberculosis Vaccines: Opportunities and Challenges

Recent Developments in Mycobacteria-Based Live Attenuated Vaccine Candidates for Tuberculosis

Enhancement Of Antituberculosis Immunity In A Humanized Model System By A Novel Virus-Vectored Respiratory Mucosal Vaccine

Progress on Development and Application of Novel Tuberculosis Vaccine

Systems Approach to Tuberculosis Vaccine Development.

Progress of research on novel vaccines against Mycobaterium tuberculosis

Current developments of therapeutic vaccines for tuberculosis

Research Advances for Virus-vectored Tuberculosis Vaccines and Latest Findings on Tuberculosis Vaccine Development

Recent efforts in the development of glycoconjugate vaccine and available treatment for tuberculosis

Mycobacterium bovis Bacille Calmette-Guérin as a Vaccine Vector for Global Infectious Disease Control

Recent Advances in the Development of Protein- and Peptide-Based Subunit Vaccines against Tuberculosis

A Summary on Tuberculosis Vaccine Development-Where to Go?

Current Development of Novel Vaccines Against Bovine Tuberculosis

Advance in strategies to build efficient vaccines against tuberculosis

Systematic Evaluation of Mycobacterium Tuberculosis Proteins for Antigenic Properties Identifies Rv1485 and Rv1705c As Potential Protective Subunit Vaccine Candidates.